Cannabis is thriving in the US, and it’s about to enter a critical time as Americans prepare to vote.

With the US presidential election right around the corner, the Investing News Network (INN) talked with a few experts to determine what investors can expect regardless of the outcome.


The presidential election this year will see President Donald Trump face off against Joe Biden, Democratic nominee and former vice president. On November 3, voters will cast their ballots to decide whether or not Trump gets another four years in office.

In this article, INN examines the ways the cannabis business may move forward in the case of a Trump re-election. Click here for our coverage of what could happen in the event of a Biden victory.

The Trump administration’s history with cannabis

Sentiment on the cannabis industry was mixed in the US after Trump’s win in 2016 — after all, Canada had yet to legalize the drug for recreational use, a move that has since paved the way forward by offering a roadmap to approach the novel drug industry.

During his campaign, Trump had sent mixed signals as to his personal level of interest in terms of cannabis policy, and after his election the confusion continued.

The biggest opposition and real moment of concern for the US industry came as Trump’s first attorney general, Jeff Sessions, reinforced his strong stance against the drug and its legalization at any level.

The disdain for cannabis from Sessions began early and included the infamous phrase, “good people don’t smoke marijuana,” said during a Senate hearing in April 2016.

Sessions’ biggest aggression against cannabis came early in 2018, when he removed a technical federal protection for cannabis state programs, enacted during the second term of Trump’s predecessor, Barack Obama. At the time, this decision sent cannabis stocks tumbling, a clear sign of the concern investors held about the impact Sessions could have on the marijuana industry and its growth.

In November 2018, Sessions resigned as attorney general, a move that again moved the needle for cannabis investments, only this time the trend was upwards.

Sessions’ departure was so well received by the industry that a room of investors even clapped and cheered to the sound of Sessions leaving the Trump administration.

Trump’s back and forth with cannabis didn’t end there, as he’s made comments on the development of cannabis regulation bills, including the STATES Act.

“I know exactly what (Colorado Senator Cory Gardner) is doing. We’re looking at it,” said Trump in mid-2018. “But I probably will end up supporting that, yes.”

Most recently, US Congress has been pushing for a vote on the MORE Act, which would deschedule cannabis under the federal government perspective.

However, like the STATES Act before it, the new legislation is expected to stall at the Senate due to the majority leadership of Republican Senator Mitch McConnell. That would prevent the bill from getting a signature from Trump and being enacted.

What does Trump think about cannabis now?

Earlier this year, a report in the Chicago Tribune indicated that according to Trump’s campaign spokesman, Marc Lotter, the president maintains a conservative mindset for the drug.

“I think the president is looking at this from a standpoint of a parent — a parent of a young person — to make sure we keep our kids away from drugs,” Lotter said at the time.

“They need to be kept illegal, that is the federal policy.”

Matt Carr, chief trends strategist at the Oxford Club, told INN that in the event of a Trump re-election he expects cannabis businesses, particularly at the state level, to continue at the same pace.

Effectively, given the lack of a federal framework, individual states have tackled the cannabis industry by either directly enacting policies or by leaving the issue to voters and asking them to determine whether or not to move forward with state programs.

This version of the market has created a fractured rollout in which no intrastate commerce is allowed. What’s more, for the companies big enough to operate in multiple states, every operation can feel like a totally different corporation.

“If Trump wins, do we have federal legalization in the next couple years? Probably not,” Carr said. “Because I think they control the White House and then the Senate; that’s kind of difficult.”

Despite these challenges, multi-state operators have established a footprint while engaging investors and gaining ground in conversations around best bets on cannabis stocks.

While being excited about the potential for federal reform, a duo of cannabis experts at fund manager Purpose Investments aren’t holding their breath for big changes given that cannabis in the US is growing with or without policy changes.

In a note issued to investors, Greg Taylor, chief investment officer and portfolio manager with Purpose Investments, alongside portfolio manager Nawan Butt, wrote:

Although there may be hurdles in cannabis reform in the US, the trajectory of current sales growth is unaffected by this. We continue to see outsized growth in most states as operators have worked out how to optimize within the current constraints. Any reform at the federal level will cause a step function in valuations of these operators, but explosive growth can still continue under current regulations.

An exchange-traded fund (ETF) manager agrees with Taylor and Butt. “Even if Trump were to win somehow, it’s not a negative for marijuana and at least has all the upside it already has right now,” Dan Ahrens, managing director and chief operating officer with AdvisorShares, told INN.

Ahrens manages the AdvisorShares Pure Cannabis ETF (ARCA:YOLO), which engages with US-operating companies publicly listed in the Canadian markets.

The ETF manager expects to see cannabis as a conversation topic this election cycle, regardless of the final result, since five states will be voting on the advancement of cannabis programs.

Investor takeaway

Trump has become an unpredictable figure, and while that has helped spread ideas about the potential for his administration to work on cannabis policy at the federal level, little has come of it.

Whether or not Trump engages with the cannabis industry — for good or bad — remains to be seen.

But experts agree that given a second term of Trump, cannabis will likely remain untouched by federal powers, meaning state programs and the companies working within them will continue to operate and even thrive with growing sales.

The growth of the industry seems poised to continue with or without Trump at the helm of the country.

Don’t forget to follow us @INN_Cannabis for real-time updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce that it has closed the 2nd and final tranche of its Unit financing. In connection with the closing, the Company issued 1,356,873 Units at a price of $0.55 per Unit, for gross proceeds of $746,280.15. Each Unit consists of one (1) common share and one (1) warrant. Each warrant entitles the holder to purchase one common share of the Company, at an exercise price of $0.75 per share, for a period of two years from the date of issuance. The warrants are subject to an acceleration right that allows the Company to give notice of an earlier expiry date if the Company’s share price on the CSE (or such other stock exchange the Company’s shares may be trading on) is equal to or greater than $1.25 for a period of 20 consecutive trading days. Finder’s fees of $42,542, 3,200 Finder’s shares and 80,550 Finder’s warrants were issued in connection with finder’s fees payable.

In total, the Company raised gross proceeds of $1,757,180 and issued 3,194,873 Units.

Keep reading... Show less

 Sweet Earth Holdings Corp. (CSE: SE) (FSE: 1KZ1) (OTCQB: SEHCF) (“Sweet Earth” the “Company”) is pleased to announce that it has received full Depository Trust Company (“DTC”) eligibility in the United States. On October 20, 2020, Sweet Earth announced that its shares had been listed on the United States’ Over-The-Counter Bulletin (“OTCQB”) under the ticker SEHCF.

DTC status means that Sweet Earth shares are now eligible to be transferred between brokerage accounts within the United States and significantly augments the ease in which American-based investors are able to trade Sweet Earth shares.

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”), announces that further to its press releases dated July 21, 2020 and July 31, 2020, the Company proposes to amend the exercise price of 19,405,804 warrants of the Company that were originally issued on July 27, 2018, to $0.10. These warrants are set to expire on December 31, 2020.

The Company had initially proposed a lower amended price, but that proposal was not approved by the TSX Venture Exchange (“Exchange“), however, the Exchange indicated that a $0.10 exercise price, may be more acceptable. Accordingly, the proposed amendment remains subject to Exchange approval.

Keep reading... Show less

Issuance of U.S. Patent No. 10,851,077 covering methods for extracting and concentrating cannabinoids using ultrasound-enhanced solvent extraction bolsters World Class’ intellectual patent portfolio

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”) is pleased to announced the United States Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 10,851,077 on December 1, 2020 in relation to the Company’s methods for extracting and concentrating cannabinoids and other target compounds from cannabis using ultrasound-enhanced solvent extraction

Keep reading... Show less

Ubican brings well-known brands and is a trusted vendor with an established sales and marketing program

Chemesis International Inc. (CSE:CSI) (OTCQB:CADMF) (FRA:CWAA) (the “Company” or “Chemesis”), announces Ubican Global (“Ubican”) as its primary supplier for its United States VICKI program. Ubican is a trusted supplier of a family of brands, each with multiple types of products. The products include tinctures, digestibles, edibles, pet, beautyskincare, topical, edible, fitness, and smokable products

Keep reading... Show less